Brett M. Hall

Immuneering (United States)

Medicine · Health Sciences

25h-index5.9kcitations123works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(25), Histone Deacetylase Inhibitors Research(21), Lymphoma Diagnosis and Treatment(20), Cancer Genomics and Diagnostics(19), Chronic Lymphocytic Leukemia Research(14)

Publications123 total

Abstract 4195: Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models
Cancer Research·2024
Supplementary Figure 3 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 5 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Methods from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 4 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Methods from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 4 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 6 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 5 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure Legends from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Table 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure Legends from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 3 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Data from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 2 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 6 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Table 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 7 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
page 1 of 7Next →

Frequent Co-authors

A. Kate Sasser(11), Amy Axel(11), Laura F. Gibson(7), Helgi van de Velde(6), Manjula Reddy(6), James Fortney(5), Tineke Casneuf(5), Kate Sasser(5), Jennifer L. Dembinski(4), Michael Andreeff(4), Frank C. Marini(4), Nicholas J. Sullivan(4), Shalini Chaturvedi(4), Adam Studebaker(3), Razelle Kurzrock(3), Thomas A. Puchalski(3), Frits van Rhee(3), José A. López-Martín(3), Rajesh Bandekar(3), Jacqueline Lieblein(3)